You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

CLINICAL TRIALS PROFILE FOR BACTRIM DS


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Bactrim Ds

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT03431168 ↗ A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV Active, not recruiting University of Alabama at Birmingham Phase 2 2018-03-07 More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes. The purpose of this randomized controlled trial is to evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to determine its efficacy and safety.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Bactrim Ds

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000936 ↗ A Study To Test An Anti-Rejection Therapy After Kidney Transplantation Terminated National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1999-11-01 Kidney transplantation is often successful. However, despite aggressive anti-rejection drug therapy, some patients will reject their new kidney. This study is designed to test two anti-rejection approaches. Two medications in this study are currently used in children, but there is no information regarding which drug is safer or more effective. Survival rates in renal transplantation are unacceptably low. Therefore, there is a need for an improved post-transplant treatment, such as the induction therapy used in this study.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed M.D. Anderson Cancer Center Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Bactrim Ds

Condition Name

Condition Name for Bactrim Ds
Intervention Trials
Leukemia 6
Abscess 4
Urinary Tract Infections 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Bactrim Ds
Intervention Trials
Infections 15
Infection 14
Communicable Diseases 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Bactrim Ds

Trials by Country

Trials by Country for Bactrim Ds
Location Trials
United States 119
France 4
Canada 3
Peru 3
Italy 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Bactrim Ds
Location Trials
Texas 18
Pennsylvania 8
Ohio 8
New York 6
Michigan 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Bactrim Ds

Clinical Trial Phase

Clinical Trial Phase for Bactrim Ds
Clinical Trial Phase Trials
Phase 4 8
Phase 3 16
Phase 2 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Bactrim Ds
Clinical Trial Phase Trials
Completed 35
Terminated 7
Not yet recruiting 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Bactrim Ds

Sponsor Name

Sponsor Name for Bactrim Ds
Sponsor Trials
M.D. Anderson Cancer Center 11
National Institute of Allergy and Infectious Diseases (NIAID) 7
National Cancer Institute (NCI) 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Bactrim Ds
Sponsor Trials
Other 113
Industry 17
NIH 17
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for BACTRIM DS

Last updated: December 31, 2024

Introduction

BACTRIM DS, a combination antibiotic consisting of sulfamethoxazole and trimethoprim, is widely used to treat various infections, including skin and soft tissue infections, urinary tract infections, and acne. This article provides an update on clinical trials, market analysis, and projections for BACTRIM DS, highlighting its safety profile, market performance, and future outlook.

Clinical Trials and Safety Profile

Recent Investigations and FDA Labeling

A significant development in the clinical trials landscape for BACTRIM DS involves the revised FDA labeling following an investigation by pediatric physicians at Children’s Mercy Kansas City and the University of Missouri-Kansas City School of Medicine. This investigation revealed cases of severe acute respiratory failure associated with BACTRIM treatment in previously healthy adolescent patients. As a result, the FDA updated the labeling to advise medical providers to watch for symptoms such as cough, shortness of breath, or rapid, shallow breathing that could indicate acute respiratory failure[1].

Genetic Predictors and Pathology Markers

The Children’s Mercy Genomic Medicine Center is conducting genetic testing to identify predictors of this rare but potentially fatal reaction. All cases evaluated so far have shown the same HLA genotype, suggesting a genetic component to the adverse reaction. This ongoing research aims to alert providers and patients to these symptoms and potentially avert serious complications[1].

Market Analysis

Current Market Performance

BACTRIM DS is part of the broader antimicrobial drugs market. While antimicrobial drugs generally have lower market sales compared to other therapeutic areas like oncology, they still play a crucial role in treating bacterial infections. The average cumulative nine-quarter sales for high-ranking antimicrobial drugs are significantly lower than those for oncology drugs, with antimicrobials averaging around $42 million in sales compared to $1,041 million for oncology drugs[2].

Cost and Generic Competition

The cost of BACTRIM DS can be managed through the use of generic versions, which become available after the exclusive marketing period for brand-name drugs expires. Generic versions of BACTRIM DS have the same active ingredients and do not require additional clinical testing, leading to lower costs for patients. Long-term use of BACTRIM DS can also be cost-effective through various savings strategies[5].

Market Projections

U.S. Clinical Trials Market

The U.S. clinical trials market, which includes trials for antimicrobial drugs like BACTRIM DS, is expected to grow significantly. The market was valued at $25.81 billion in 2023 and is projected to reach $41.57 billion by 2033, growing at a CAGR of 4.88% during the forecast period. While the oncology segment dominates this market, antimicrobial drugs will continue to be an essential part of clinical trials due to the ongoing need for effective treatments against bacterial infections[3].

Segment Growth

Phase I studies, which are critical for assessing the safety and pharmacokinetics of new drugs, are expected to register the fastest CAGR growth of 7.2% during the forecast period. This growth underscores the importance of early-stage clinical trials in the development of new antimicrobial drugs, including potential successors or alternatives to BACTRIM DS[3].

Market Dynamics

Drivers

The pharmaceutical industry's investment in clinical trials drives innovation in drug development. FDA guidance ensures that trials adhere to stringent protocols, enhancing patient safety and data integrity. The need for effective antimicrobial treatments, particularly in the face of rising antibiotic resistance, continues to drive research and development in this area[3].

Restraints

Challenges in the U.S. clinical trials market include the high costs associated with conducting trials and the potential for rare side effects to manifest only in later trial phases. These challenges highlight the need for continued vigilance and rigorous monitoring during all phases of clinical trials[3].

Key Takeaways

  • Revised FDA Labeling: BACTRIM DS labeling has been updated to include warnings about potential acute respiratory failure, emphasizing the importance of monitoring patients for respiratory symptoms.
  • Genetic Predictors: Ongoing research aims to identify genetic predictors of adverse reactions to BACTRIM DS, which could help in early intervention.
  • Market Performance: Antimicrobial drugs, including BACTRIM DS, have lower market sales compared to oncology drugs but remain crucial for treating bacterial infections.
  • Cost Management: Generic versions and long-term use strategies can help manage the cost of BACTRIM DS.
  • Market Growth: The U.S. clinical trials market is expected to grow, with Phase I studies showing the fastest growth rate.

FAQs

What is the current safety concern with BACTRIM DS?

The current safety concern with BACTRIM DS involves cases of severe acute respiratory failure in previously healthy adolescent patients. The FDA has updated the labeling to advise medical providers to watch for symptoms such as cough, shortness of breath, or rapid, shallow breathing[1].

How does the cost of BACTRIM DS compare to its generic versions?

Generic versions of BACTRIM DS are generally cheaper because they do not require additional clinical testing and can be produced after the exclusive marketing period for brand-name drugs expires[5].

What is the projected growth of the U.S. clinical trials market?

The U.S. clinical trials market is projected to grow from $27.07 billion in 2024 to $41.57 billion by 2033, with a CAGR of 4.88% during the forecast period[3].

Which segment of clinical trials is expected to grow the fastest?

Phase I studies are expected to register the fastest CAGR growth of 7.2% during the forecast period due to their critical role in assessing the safety and pharmacokinetics of new drugs[3].

What are the main drivers of the clinical trials market?

The main drivers include pharmaceutical companies' investments in clinical trials, the need for innovative healthcare solutions, and the imperative to enhance patient care and safety[3].

Sources

  1. Children's Mercy Research Institute: "Children's Mercy Physicians' Investigation Prompts Revised FDA Labeling for Bactrim, Septra"[1].
  2. ASPE: "Antimicrobial Drugs Market Returns Analysis Final Report"[2].
  3. Biospace: "U.S. Clinical Trials Market Size Industry Analysis Report, 2033"[3].
  4. FDA: "BACTRIM™ sulfamethoxazole and trimethoprim DS (double strength) Tablets"[4].
  5. Healthline: "Bactrim Cost 2024: Coupons and More"[5].

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.